ADA Scientific Sessions 2025 Abstract

The Efficacy and Safety of Dapaglifrozin in Type 1 Diabetic Patients with Diabetic Kidney Disease in Zhongshan, China

By Baile Zhu, Liling Qiu, Qing Ye, Wenjing Wu, Chuan Yang

Trial in peopleInterventions

The paper

Baile Zhu, Liling Qiu, Qing Ye, Wenjing Wu, Chuan Yang

Zhongshan

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, poster 414-P

doi.org/10.2337/db25-414-p

Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk